Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal HBV Vaccination with Imiquimod in Cirrhotic Non-Responders
NCT05028322Phase 2Unknown
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
01
Overview
A Phase 2 trial of imiquimod in hepatitis B (HBV), sponsored by CHRU de Nancy - Hôpital Central. Status: unknown.
02
Drugs
imiquimod
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05028322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028322.